Absci Corp expected to post a loss of 20 cents a share - Earnings Preview
Absci Corp expected to post a loss of 20 cents a share - Earnings Preview
Absci Corp ABSI.OQ ABSI.O is expected to show a rise in quarterly revenue when it reports results on August 11 for the period ending June 30 2026
The Vancouver Washington Washington-based company is expected to report a 97.2% increase in revenue to $1.169 million from $593 thousand a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for Absci Corp is for a loss of 20 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Absci Corp is $14.00, about 68.7% above its last closing price of $8.30
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -0.22 | -0.21 | -0.19 | Beat | 9.5 |
Dec. 31 2026 | -0.19 | -0.19 | -0.20 | Missed | -2.9 |
Sep. 30 2025 | -0.23 | -0.21 | -0.20 | Beat | 5.5 |
Jun. 30 2025 | -0.21 | -0.21 | -0.24 | Missed | -13.2 |
Mar. 31 2025 | -0.23 | -0.23 | -0.21 | Beat | 8.7 |
Dec. 31 2024 | -0.21 | -0.24 | -0.25 | Missed | -4.8 |
Sep. 30 2024 | -0.22 | -0.21 | -0.24 | Missed | -15.4 |
Jun. 30 2024 | -0.19 | -0.19 | -0.22 | Missed | -12.8 |
This summary was machine generated August 7 at 20:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on AbSci
See all newsAbsci Corp reports results for the quarter ended September 30 - Earnings Summary
Brief: Absci Corp Files For Mixed Shelf Size Not Disclosed - SEC Filing
Absci Q3 revenue misses estimates, net loss widens on R&D spends
Focus: Beyond the Scale: Men turn to cosmetic clinics to complete weight-loss transformation
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave